Sight Sciences, Inc., (SGHT): Price and Financial Metrics


Sight Sciences, Inc., (SGHT): $11.86

-0.27 (-2.23%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SGHT POWR Grades

  • Sentiment is the dimension where SGHT ranks best; there it ranks ahead of 49.09% of US stocks.
  • SGHT's strongest trending metric is Value; it's been moving down over the last 179 days.
  • SGHT's current lowest rank is in the Quality metric (where it is better than 11.57% of US stocks).

SGHT Stock Summary

  • With a one year PEG ratio of 0.49, SIGHT SCIENCES INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than merely 4.18% of US stocks.
  • SIGHT SCIENCES INC's stock had its IPO on July 15, 2021, making it an older stock than only 3.77% of US equities in our set.
  • With a price/sales ratio of 8.92, SIGHT SCIENCES INC has a higher such ratio than 86.28% of stocks in our set.
  • Stocks that are quantitatively similar to SGHT, based on their financial statements, market capitalization, and price volatility, are XGN, CSII, ECOR, SNES, and AXGN.
  • To check out SIGHT SCIENCES INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001531177.

SGHT Valuation Summary

  • SGHT's price/earnings ratio is -6.6; this is 129.86% lower than that of the median Healthcare stock.
  • Over the past 19 months, SGHT's price/earnings ratio has gone up 37.1.

Below are key valuation metrics over time for SGHT.

Stock Date P/S P/B P/E EV/EBIT
SGHT 2023-01-30 8.6 3.3 -6.6 -4.9
SGHT 2023-01-27 9.4 3.6 -7.3 -5.6
SGHT 2023-01-26 9.1 3.4 -7.0 -5.3
SGHT 2023-01-25 8.9 3.4 -6.8 -5.2
SGHT 2023-01-24 9.2 3.5 -7.0 -5.4
SGHT 2023-01-23 9.0 3.4 -6.9 -5.2

SGHT Price Target

For more insight on analysts targets of SGHT, see our SGHT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $43.67 Average Broker Recommendation 1.5 (Moderate Buy)

SGHT Stock Price Chart Interactive Chart >

Price chart for SGHT

SGHT Price/Volume Stats

Current price $11.86 52-week high $18.25
Prev. close $12.13 52-week low $5.35
Day low $11.79 Volume 51,900
Day high $12.05 Avg. volume 121,673
50-day MA $12.13 Dividend yield N/A
200-day MA $9.25 Market Cap 571.07M

Sight Sciences, Inc., (SGHT) Company Bio


Sight Sciences, Inc., an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology, for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.


SGHT Latest News Stream


Event/Time News Detail
Loading, please wait...

SGHT Latest Social Stream


Loading social stream, please wait...

View Full SGHT Social Stream

Latest SGHT News From Around the Web

Below are the latest news stories about SIGHT SCIENCES INC that investors may wish to consider to help them evaluate SGHT as an investment opportunity.

Sight Sciences Announces 1,000th TearCare® Customer Installation

Over 1,000 Professional Eye Care Practices Have integrated the TearCare® System to Treat Root Cause of Dry Eye Disease due to Meibomian Gland Dysfunction (MGD) Over 1,000 Professional Eye Care Practices Have integrated the TearCare® System to Treat Root Cause of Dry Eye Disease due to Meibomian Gland Dysfunction (MGD)

GlobeNewswire | January 26, 2023

Sight Sciences Announces 1,000th TearCare Customer Installation

Over 1,000 Professional Eye Care Practices Have integrated the TearCare System to Treat Root Cause of Dry Eye Disease due to Meibomian Gland Dysfunction (MGD) MENLO PARK, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”) an eyecare technology company focused on creating innovative solutions intended to transform care

Wallstreet:Online | January 26, 2023

Sight Sciences expects Q4 topline to surge 40% Y/Y

Eyecare technology company focused on creating innovative solutions, Sight Sciences (SGHT) expects Q4 revenue to be in the range of $20.4M-20.6M, an increase of 40% Y/Y and +10% vs

Seeking Alpha | January 10, 2023

Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results

Company Also Announces CFO Transition Company Also Announces CFO Transition

GlobeNewswire | January 9, 2023

Sight Sciences (NASDAQ:SGHT) adds US$55m to market cap in the past 7 days, though investors from a year ago are still down 17%

It is doubtless a positive to see that the Sight Sciences, Inc. ( NASDAQ:SGHT ) share price has gained some 139% in the...

Yahoo | January 9, 2023

Read More 'SGHT' Stories Here

SGHT Price Returns

1-mo -1.82%
3-mo 5.14%
6-mo 22.14%
1-year -32.31%
3-year N/A
5-year N/A
YTD -2.87%
2022 -30.51%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7983 seconds.